DocG DocG | AI-Powered Clinical Summaries
← DocG Medical Summaries

Top Allergy & Immunology Research Papers

Live ranking — trailing 6 months, each paper's latest score Scores fold Allergy & Immunology Relevance & Applicability into the quality dimensions; papers scored before the dynamic-specialty rubric keep their original score Showing the top 10 of 158 ranked articles — sign in free for the full ranking and per-criterion score breakdowns
1. 7.2
Resensitization of β-Lactams After Negative Initial Standard Evaluation: A Systematic Review and Meta-Analysis.
Overall: This sizable systematic review supports a practical recommendation against routine beta-lactam allergy retesting after a negative evaluation, although heterogeneous evidence and limited direct patient-outcome data reduce certainty.
2. 6.9
First-trimester asthma controller medication use and major congenital malformation risk in offspring of women with asthma: A nationwide population-based cohort study.
Overall: This large US observational cohort addresses an important pregnancy-safety question using patient-important outcomes, but incomplete quantitative reporting and a residual safety signal limit confidence and practice-changing impact.
3. 6.8
Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study.
Overall: This US phase 4 study reports large, patient-important improvements across diverse severe-asthma populations, but its uncontrolled pre-post design substantially limits causal certainty.
4. 6.8
Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S.
Overall: This small uncontrolled extension provides clinically relevant evidence that oral sebetralstat is practical and well tolerated for breakthrough hereditary angioedema attacks, but comparative efficacy and precise net benefit remain uncertain.
5. 6.7
Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1/-2 Studies.
Overall: Depemokimab produced sustained improvements in exacerbations and several patient-centered outcomes with convenient twice-yearly dosing, but incomplete absolute-effect and safety reporting and the specialty-oriented nature of biologic asthma care limit immediate US primary-care impact.
6. 6.6
Risk Factors for the Development of Food Allergy in Infants and Children: A Systematic Review and Meta-Analysis.
Overall: Risk Factors for the Development of Food Allergy in Infants and Children: A Systematic Review and Meta-Analysis provides a rigorous and clinically relevant synthesis, but its largely observational findings offer limited direct evidence that risk-based interventions improve patient outcomes.
7. 6.4
Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies.
Overall: This large and precise patient-level analysis questions reliance on symptom scores alone, but the observed prognostic association is modest and no outcome-improving management strategy was tested.
8. 6.4
Comparative Efficacy of Subcutaneous and Sublingual Allergen Immunotherapy for Grass Pollen-Induced Allergic Rhinoconjunctivitis: Pairwise and Adjusted Indirect Treatment Comparison of Standardized ALK Products.
Overall: This systematic comparison is clinically relevant and based on randomized trials, but indirect comparisons, heterogeneity, missing precision and safety data, and uncertain absolute clinical benefit limit its ability to change practice.
9. 6.4
Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial.
Overall: The trial shows a large reduction in hereditary angioedema attacks with acceptable short-term tolerability, but its very small sample, short follow-up, investigational therapy, and limited relevance to routine primary care constrain its overall importance.
10. 6.3
Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials.
Overall: Large, rigorous trials address a common outpatient problem, but the truncated abstract omits the quantitative efficacy and safety information needed to establish meaningful net benefit.
Score Guide: 9-10 Exceptional 7-8 Strong 5-6 Moderate 3-4 Weak 1-2 Poor

Get the top Allergy & Immunology papers in your inbox

Free 300-word clinical summaries 3× per week, plus the full ranking of all 158 recent Allergy & Immunology papers with per-criterion AI score breakdowns.

Sign Up Free